Cooper, N.; Guterres, S.; Pochopień, M.; Wilson, K.; James, S.; Toumi, M.; Tytuła, A.; Rich, C.; Eriksson, D.
The Cost-Effectiveness of Avatrombopag Versus Eltrombopag and Romiplostim in the Treatment of Patients with Immune Thrombocytopenia in the UK. J. Mark. Access Health Policy 2025, 13, 11.
https://doi.org/10.3390/jmahp13020011
AMA Style
Cooper N, Guterres S, Pochopień M, Wilson K, James S, Toumi M, Tytuła A, Rich C, Eriksson D.
The Cost-Effectiveness of Avatrombopag Versus Eltrombopag and Romiplostim in the Treatment of Patients with Immune Thrombocytopenia in the UK. Journal of Market Access & Health Policy. 2025; 13(2):11.
https://doi.org/10.3390/jmahp13020011
Chicago/Turabian Style
Cooper, Nichola, Sebastian Guterres, Michał Pochopień, Koo Wilson, Sam James, Mondher Toumi, Anna Tytuła, Carly Rich, and Daniel Eriksson.
2025. "The Cost-Effectiveness of Avatrombopag Versus Eltrombopag and Romiplostim in the Treatment of Patients with Immune Thrombocytopenia in the UK" Journal of Market Access & Health Policy 13, no. 2: 11.
https://doi.org/10.3390/jmahp13020011
APA Style
Cooper, N., Guterres, S., Pochopień, M., Wilson, K., James, S., Toumi, M., Tytuła, A., Rich, C., & Eriksson, D.
(2025). The Cost-Effectiveness of Avatrombopag Versus Eltrombopag and Romiplostim in the Treatment of Patients with Immune Thrombocytopenia in the UK. Journal of Market Access & Health Policy, 13(2), 11.
https://doi.org/10.3390/jmahp13020011
